Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: Propensity score analysis

Abstract

As postoperative adjuvant TACE does not improve overall survival or reduce recurrence in HCC patients, further study is needed to clarify its clinical benefit.

Feasibility of combining adjuvant transarterial chemoembolization with nucleos(t)ide analog therapy for patients with HBV-associated hepatocellular carcinoma after hepatectomy

“…However, adjuvant TACE actually reduced the overall survival of patients with a single tumor <5 cm without microvascular invasion. This lack of clinical benefit was confirmed in a more recent retrospective study (16) involving 229 patients with HCC lacking factors associated with elevated risk of recurrence or reduced overall survival. Adjuvant TACE did not improve the overall survival or reduce recurrence.…”

“…Based on the indications for adjuvant TACE or postoperative NA monotherapy on their own, patients who have HBV-associated, relatively early-stage HCC and who are at high risk of recurrence may be the most suitable candidates for the two therapies combined. Adjuvant TACE is not, however, recommended for patients who have early-stage HBV-associated HCC and who lack risk factors of recurrence (15,16). Combination therapy may also be appropriate for patients with HBV-associated HCC in advanced stages.…”

Prognostic nomogram for patients with hepatocellular carcinoma underwent adjuvant transarterial chemoembolization following curative resection

“…[4,10,11] A meta-analysis reviewed 6 randomized control trials (RCT) and demonstrated adjuvant TACE improved survival in HCC patients with tumor size > 5 cm or vascular invasion. [4] However, in a retrospective propensity score analysis based on an HCC cohort without satellite nodules and vascular invasion, adjuvant TACE showed no superiority in terms of the survival rate and the recurrence rate.…”

“…[4] However, in a retrospective propensity score analysis based on an HCC cohort without satellite nodules and vascular invasion, adjuvant TACE showed no superiority in terms of the survival rate and the recurrence rate. [11] Although no large-scale, multi-centered RCTs were available to address the issue, several studies based on HCC patients with more tumor numbers, larger tumor size, and vascular invasion were in favor of adjuvant TACE. [10,12–15] Therefore, adjuvant TACE (1–3 courses) is widely used in postoperative HCC patients with a range of recurrence risk factors such as large tumor size, microvascular invasion (MVI), multiple tumor nodules, and satellite lesions.…”

Stratified aspartate aminotransferase-to-platelet ratio index accurately predicts survival in hepatocellular carcinoma patients undergoing curative liver resection

“…[5][6][7][8] Background liver inflammation and fibrosis play critical roles in the process of hepatocarcinogenesis and survival after hepatectomy. [9][10][11] Few studies have aimed to assess the prognostic potential of these and other factors comprehensively and systematically.…”